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Abstract
Repeat episodes of infective endocarditis (IE) can occur in patients who survive an initial episode. We analysed risk factors and 1-year
mortality of patients with repeat IE. We considered 1874 patients enrolled in the International Collaboration on Endocarditis – Prospective
Cohort Study between January 2000 and December 2006 (ICE-PCS) who had deﬁnite native or prosthetic valve IE and 1-year follow-up.
Multivariable analysis was used to determine risk factors for repeat IE and 1-year mortality. Of 1874 patients, 1783 (95.2%) had
single-episode IE and 91 (4.8%) had repeat IE: 74/91 (81%) with new infection and 17/91 (19%) with presumed relapse. On bivariate analysis,
repeat IE was associated with haemodialysis (p 0.002), HIV (p 0.009), injection drug use (IDU) (p < 0.001), Staphylococcus aureus IE
(p 0.003), healthcare acquisition (p 0.006) and previous IE before ICE enrolment (p 0.001). On adjusted analysis, independent risk factors
were haemodialysis (OR, 2.5; 95% CI, 1.2–5.3), IDU (OR, 2.9; 95% CI, 1.6–5.4), previous IE (OR, 2.8; 95% CI, 1.5–5.1) and living in the North
American region (OR, 1.9; 95% CI, 1.1–3.4). Patients with repeat IE had higher 1-year mortality than those with single-episode IE (p 0.003).
Repeat IE is associated with IDU, previous IE and haemodialysis. Clinicians should be aware of these risk factors in order to recognize
patients who are at risk of repeat IE.
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Background
Repeat infective endocarditis (IE) is a major complication that
can occur in patients who have recovered from an initial
episode [1–3]. The lifetime rate of recurrent or ‘repeat IE’
(terminology proposed by this group [4]) is estimated to be
between 2% and 31% [5–7]. Previous studies have identiﬁed
risk factors for repeat IE such as intravenous drug use (IDU)
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[1,6,8], congenital and rheumatic heart disease [6–8], prior
episode(s) of endocarditis [5], chronic dialysis [2], male
gender and increasing of age (>65 years) [9]. Among patients
who undergo surgical treatment for IE, prosthetic valve
endocarditis, positive valve culture at surgery and persistence
of fever at the seventh postoperative day have been shown
to be predictive of repeat IE [10]. The interpretation of
these ﬁndings, however, is limited by inconsistent deﬁnitions
of repeat IE, in general, and inconsistent deﬁnitions of
relapse vs. re-infection among patients who have a repeat
episode of IE due to the same bacterial species as the initial
episode.
Among patients who experience a repeat episode of IE
due to the same bacterial species, molecular methods, such
as PFGE, can be used to differentiate relapse from re-infec-
tion [4]. Nevertheless, molecular methods are usually
impractical in the clinical setting and therefore the
time-interval between IE episodes is typically used to
distinguish between relapse and re-infection. For example,
an episode of IE caused by the same species within 6 months
of the initial episode would be considered a relapse, while an
episode of IE caused by the same species >6 months from
the initial episode would be considered a re-infection
[4,6,8,9,11]. Both 3-month and 6-month time-interval-based
deﬁnitions have been used. This group found an agreement
of 77% between the 6-month time-interval-based classiﬁca-
tion and the molecular-based classiﬁcation in a small,
well-deﬁned cohort [4].
The epidemiology of IE has shifted such that health-
care-associated infections [12,13] and infections in older
populations, with a higher median age at IE onset [14], feature
prominently. With these changes a better contemporary
understanding of the incidence and risk factors for repeat IE
is needed [14–16]. The purpose of this study was to describe
the clinical characteristics, identify risk factors and examine
1-year mortality of patients with repeat IE in a large,
contemporary cohort.
Methods
ICE – PCS
This analysis is based on the International Collaboration on
Endocarditis – Prospective Cohort Study (ICE – PCS), a
prospective, multicentre database of patients with IE. From
January 2000 to September 2006, 5594 patients with possible
or deﬁnite endocarditis according to the Duke criteria [17,18]
were enrolled. The ICE – PCS database consists of data from
64 sites, in 28 countries worldwide. Details regarding patient
enrollment have been previously reported [16].
Deﬁnitions
Presumed IE relapse was deﬁned as a new episode caused by
the same bacterial species, within 6 months of the ﬁrst
episode. Presumed new infection was deﬁned as a new IE
episode caused by a different bacterial species or by the same
bacterial species >6 months from the initial episode
[4,6,8,9,11]. We deﬁned the interval between IE episodes as
the number of days between the dates of admission for IE or
the date of IE-related fever onset if it was hospital-acquired.
We included new IE cases occurring at least 10 weeks from
the initial episode. This threshold was chosen arbitrarily as we
assumed that 4 weeks beyond a 6-week treatment course
would be a reasonable interval for having a new IE episode not
related to suboptimal treatment of the initial infection.
Community-acquired IE was deﬁned as signs or symptoms
of IE developing before hospitalization in a patient without
extensive out-of-hospital healthcare contact. Nosocomial
healthcare-associated IE was deﬁned as IE occurring in a
patient hospitalized for more than 48 h. Non-nosocomial
healthcare-associated IE was deﬁned as the diagnosis of IE
within 48 h of admission speciﬁcally in patients who, before
the onset of IE: (i) received intravenous therapy or specialized
nursing care within 30 days; (ii) received haemodialysis; (iii)
were hospitalized for at least 2 days in the preceding 90 days,
or (iv) resided in a long-term care facility [15,16].
Patient selection
Patients from the ICE – PCS with a diagnosis of deﬁnite IE on a
native or prosthetic valve and with 1-year follow-up were
considered (Fig. 1). We excluded patients who had missing
data at 1-year follow-up (2521/5594, 45%). We also excluded
patients with intra-cardiac lead IE (n = 270), because a repeat
episode of IE could be related to a retained device [19,20] and
patients (n = 49) who lacked information on type of IE (e.g.
native vs. prosthetic vs. intra-cardiac lead).
We distinguished patients with only one episode of IE
(‘single-episode’ IE) from those with more than one episode
(‘repeat’ IE) and we distinguished presumed relapse from
presumed new infection [4,6,8,9,11]. Among 174 patients with
repeat IE, only patients with documented deﬁnite IE for both
episodes were included (Fig. 1).
Weexcluded the following patients: 71 (41%)with insufﬁcient
data to validate a repeat IE episode; eight (0.4%) with a bacterial
culture negative for the suspected second episode because it
was impossible to differentiate between relapse and new
infection due to the patients’ complex medical history; and four
(0.2%) with the relapse episodewithin 10 weeks of the ﬁrst one.
Wemade two exceptionswith the 10-week repeat IE criteria: (i)
a patient with a second episode 58 days after the initial episode
because a complete recovery was documented, clinically and by
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echocardiography, 56 days after the initial episode; (ii) a patient
with a second episode 8 weeks after the initial episode because
recovery was documented after completing medical and surgical
treatment. Taking into account the criteria above, a total of 1874
patients were included in this analysis.
Statistical analysis
Continuous variables are presented as medians with 25th and
75th percentiles. Categorical variables are presented as fre-
quencies and percentages of the speciﬁc group. Statistical
signiﬁcance of bivariate comparisons was evaluated using the
Fisher’s exact test. Patients with presumed IE relapse were
compared with patients with presumed new infection; patients
with repeat IE were compared with patients with single-episode
IE. Multiple logistic regression models were ﬁt to determine
factors that were associated with repeat IE as well as for
mortality. Variables found in the bivariate analyses to have an
association with the outcome of interest (i.e. repeat IE and
death) (p < 0.20) were considered for the ﬁnal models in a
stepwise fashion. The variables included in the ﬁnal adjusted
regression models were selected according to a combination of
statistical signiﬁcance (p < 0.05) and clinical judgement. Final
parameters estimates are reported as odds ratios (ORs) with
corresponding 95%Wald conﬁdence intervals (CIs). For all tests,
statistical signiﬁcance was determined at the 0.05 level. Kaplan
Meier survival curves were used to examine 1-year survival
among the two groups. All statistical analyses were performed
using SAS software version 9.2 (SAS Institute, Cary, NC, USA).
Results
Out of 1874 patients, 1783 (95.2%) had one IE episode while
91 (4.8%) had a documented episode of repeat IE. Table 1
FIG. 1. Selection of patients with repeat IE.
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shows the characteristics of the 91 patients with repeat IE, of
whom 74 (81%) were clinically classiﬁed as having a new
infection and 17 (19%) as having a presumed relapse. Repeat IE
occurred most commonly on the native valve (n = 75, 82%)
and was signiﬁcantly associated with infection due to S. aureus
(p 0.003). Major co-morbid medical conditions were haemod-
ialysis dependence (n = 12; 13%), diabetes mellitus (n = 19;
23%), HIV infection (n = 6; 6.6%), IDU (n = 23; 25%), history
of previous IE before enrollment into the ICE – PCS (n = 17;
19%), and history of congenital heart disease (n = 8; 8.7%).
Compared to patients with new infection, patients with
presumed relapse were more likely to have a native valve IE for
the initial episode (p 0.03), S. aureus IE (p < 0.001) and
healthcare-associated infection (nosocomial and non-nosoco-
TABLE 1. Clinical characteristics of
patients with repeat endocarditis:
bivariate analysis comparing pre-
sumed relapseavs. presumed new
infectiona
Repeat IE
Presumed
new infection
Presumed
relapse p-value
Sample [n (%)] 91 (4.8) 74 (4) 17 (0.8)
Time to repeat IE [mean days (SD)] 293 337 (248) 104 (36) ND
Time to repeat IE by organism [mean days (SD)]
S. aureus 184 282 (180) 102 (37)
Coagulase-negative Staphylococcus 577 (381) 0
Viridans group Streptococcus 258 276 (238) 122 (122) ND
S. bovis 521 (329) 0
Enterococcus 311 (191) 0
Other Streptococcus 409 (446) 0
Fungi 581 0
Time to recurrence [mean days (SD)]
Haemodialysis patients (HD) 210 (173) ND ND
Intravenous drug users (IDU) 373 (431) ND ND
Male sex 63 (69) 53 (72) 10 (59) 0.4
Age [median (25th–75th percentiles)] 51 (37–66) 51 (37–66) 49 (33–66) 0.48
Geographical regions [n (%)]
North America 29 (32) 21 (28.3) 8 (47)
South America 3 (3.3) 3 (4) 0 0.53
Europe 37 (41) 32 (43) 5 (29)
Australia/Asia/New Zealand 19 (21) 15 (20) 4 (23)
Middle East/Africa 3 (3.3) 3 (4) 0
Type of valve IE [n (%)]
Native valve IE 75 (82) 58 (78) 17 (100) 0.03
Prosthetic valve IE 16 (18) 16 (22) 0
Haemodialysis dependent [n (%)] 12 (13) 8 (11) 4 (23) 0.23
Diabetes mellitus [n (%)] 19 (23) 14 (19) 5 (29) 0.34
HIV infection [n (%)] 6 (6.6) 4 (5) 2 (12) 0.32
IDU [n (%)] 23 (25) 18 (24) 5 (29) 0.76
History of previous endocarditis [n (%)] 17 (19) 17 (23) 0 0.03
History of congenital heart disease [n (%)] 8 (8.7) 7 (9) 1 (6) 1
Microorganism [n (%)]
S. aureus 37 (41) 22 (30) 15 (88) <0.001
Coagulase-negative Staphylococcus 9 (9.9) 9 (12) 0 0.2
Viridans group Streptococcus 17 (19) 15 (20) 2 (12) 0.51
Other Streptococcus 8 (8.8) 4 (5) 0 1
S. bovis 4 (4.4) 4 (5) 0 1
Enterococcus 9 (9.9) 9 (12) 0 0.2
HACEK 0 0 0 ND
Fungi 1 (1) 1 (1.3) 0 1
Echocardiographic ﬁndings of vegetation on: [n (%)]
Aortic valve 38 (43) 35 (47) 3 (18) 0.05
Mitral valve 29 (32) 22 (30) 7 (41) 0.38
Tricuspid valve 22 (24) 16 (22) 6 (35) 0.2
Pulmonary valve 3 (3.3) 3 (4) 0 1
Myocardial wall 0 0 0 ND
Chordae 0 0 0 ND
Paravalvular complication [n (%)]
Perforation 9 (9.9) 6 (8.1) 3 (18) 0.36
Abscess 7 (7.7) 6 (8.1) 1 (5.6) 1
Intracardiac ﬁstula 2 (2.1) 2 (2.7) 0 1
Prosthetic paravalvular complications [n (%)]
Dehiscence 2 (2.2) 2 (2.7) 0 1
New regurgitation 2 (2.2) 2 (2.7) 0 1
Presumed place of acquisition [n (%)]
Community 70 (76) 61 (82) 9 (53)
Hospital healthcare 5 (5.5) 3 (4) 2 (12) 0.01
Non-hospital healthcare 14 (15) 8 (11) 6 (35)
Cardiac surgery during this hospitalization [n (%)] 40 (44) 35 (47) 5 (29) 0.27
Cardiac surgery during 1-year follow-up
(after discharge) [n (%)]
16 (18) 12 (16) 4 (23) 0.49
Complications [n (%)]
Stroke 12 (13) 11 (15) 1 (5.8) 0.45
Embolization 25 (27) 18 (24) 7 (41) 0.23
Heart failure 22 (24) 17 (23) 5 (29) 0.55
Intracardiac abscess 10 (11) 8 (11) 2 (12) 1
Persistent positive blood cultures 10 (11) 8 (11) 2 (12) 1
ND, not determined.
aClinical characteristics correspond to the initial episode.
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mial, p 0.01). Patients with new infection were more likely
than patients with relapse to have a history of previous IE
before enrollment into the ICE – PCS study (p 0.03) (Table 1).
The bivariate analysis comparing patients with repeat IE
with patients with single-episode IE is shown in Table 2.
Patients with repeat IE were more likely to be younger
(p 0.001), from North America (p < 0.001), haemodialysis
dependent (p 0.002) and HIV infected (p 0.009), have a
history of IDU (p < 0.001) and previous endocarditis before
enrollment into the ICE – PCS (p 0.001), have S. aureus IE
(p 0.003) and have a tricuspid valve involvement (p < 0.001).
Repeat IE was more likely to be associated with non-noso-
comial healthcare acquisition rather than nosocomial or
community acquisition (p 0.006) and with cardiac surgery
performed after discharge during the 1-year follow-up
(p < 0.001).
According to the multivariable model (Table 2), patient
characteristics independently associated with repeat IE were
haemodialysis (OR, 2.5; 95% CI, 1.2–5.3), IDU (OR, 2.9;95%
CI, 1.6–5.4), history of previous IE (OR, 2.8%; CI, 1.5–5.1) and
geographical distribution (North America vs. Europe; OR, 1.9;
95% CI, 1.1–3.4).
One-year survival for patients with repeat IE was 80%
compared with 91% for patients with single episode IE
(p 0.0034) (Fig. 2). According to the multivariate model that
analysed mortality stratiﬁed by predisposing factors, we found
Single
episode IE Repeat IE p-value
Multivariate
model odds
ratio (95CI)
Sample [n (%)] 1783 (95) 91 (4.8)
Male sex [n (%)] 1213 (68) 63 (69) 0.90
Age median
(25th–75th percentiles), yr
58.65 (45–71) 50.94 (38–66) 0.001
Geographical regions [n (%)] vs. Europe
North America 239 (13) 29 (32) 1.9 (1.1–3.4)
South America 200 (11) 3 (3.3) 0.3 (0.1–1.1)
Europe 815 (46) 37 (41) <0.001
Australia/Asia/New Zealand 486 (27) 19 (21) 0.7 (0.4–1.3)
Middle East/Africa 43 (2.4) 3 (3.3) 1.2 (0.3–5.3)
Type of valve IE [n (%)]
Native valve IE 1352 (76) 75 (82) 0.17
Prosthetic valve IE 431 (24) 16 (18)
Haemodialysis dependent [n (%)] 84 (4.7) 12 (13) 0.002 2.5 (1.2–5.3)
Diabetes mellitus [n (%)] 256 (14) 19 (23) 0.09
HIV infection [n (%)] 33 (1.8) 6 (6.6) 0.009
IDU [n (%)] 150 (8.2) 23 (25) <0.001 2.9 (1.6–5.4)
History of previous endocarditis [n (%)] 135 (7.4) 17 (19) 0.001 2.8 (1.5–5.1)
History of congenital heart disease [n (%)] 165 (9.2) 8 (8.7) 1.00
Microorganism [n (%)]
S. aureus 467 (26) 37 (41) 0.003
Coagulase-negative Staphylococcus 123 (6.9) 9 (9.9) 0.28
Viridans group Streptococcus 386 (21) 17 (19) 0.60
S. bovis 139 (7.8) 4 (4.4) 0.31
Other Streptococcus 102 (5.8) 4 (4.4) 0.81
Enterococcus 168 (9.4) 9 (9.9) 0.85
HACEK 28 (1.5) 0 0.4
Fungi 21 (1.1) 1 (1) 1
Echocardiographic ﬁndings of vegetation on [n (%)]
Aortic valve 739 (41) 38 (43) 1
Mitral valve 774 (43) 29 (32) 0.03
Tricuspid valve 172 (9.6) 22 (24) <0.001
Pulmonary valve 16 (0.9) 3 (3.3) 0.06
Myocardial wall 18 (1) 0 1
Chordae 18 (1) 0 1
Paravalvular complication [n (%)]
Perforation 200 (11) 9 (9.9) 0.86
Abscess 276 (15) 7 (7.7) 0.04
Intracardiac ﬁstula 43 (2.4) 2 (2.1) 1
Prosthetic paravalvular complications [n (%)]
Dehiscence 77 (4.3) 2 (2.2) 0.32
New regurgitation 101 (5.6) 2 (2.2) 0.16
Presumed place of acquisition [n (%)]
Community 1389 (78) 70 (76) 0.006
Hospital healthcare 197 (11) 5 (5.5)
Non-hospital healthcare 106 (6) 14 (15)
Multiple source 4 (0.2) 0
Cardiac surgery during this hospitalization [n (%)] 903 (51) 40 (44) 0.19
Cardiac surgery during 1-year follow-up
(after discharge) [n (%)]
94 (5.2) 16 (18) <0.001
Complications [n (%)]
Stroke 284 (16) 12 (13) 0.55
Embolization 424 (24) 25 (27) 0.44
Heart failure 507 (28) 22 (24) 0.40
Intracardiac abscess 271 (15) 10 (11) 0.29
Persistent positive
blood cultures
118 (6.6) 10 (11) 0.13
aClinical characteristics correspond to the initial episode.
TABLE 2. Bivariate and multivari-
ate analysis comparing patients with
single-episode IE (No Repeat IE) vs.
patients with repeat IEa
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haemodialysis (OR, 5.1%; CI, 1.0–24) to be an independent risk
factor for death among patients with repeat IE.
Discussion
In this contemporary multicentre study, we found that the rate
of repeat IE was 4.8%. If we were to include patients without
data to verify the repeat episode of IE, then the rate of repeat
IE would be 8.9%. Our ﬁndings are within the range of recent
studies suggesting an incidence between 4% and 12% [3,5,7,9].
The variability in repeat IE rates is likely to be due to different
patient populations, such as those with a history of IDU, the
proportion of healthcare-associated cases and potentially
different preventative strategies in selected high-risk condi-
tions.
Repeat IE appears to affect speciﬁc groups of patients
[2,6,10]. In this study, the diagnosis of repeat IE was associated
with IDU (OR, 2.9; 95% CI, 1.6–5.4), history of previous IE
(OR, 2.8; 95% CI, 1.5–5.1), haemodialysis dependence (OR,
2.5; 95% CI, 1.2–5.3) and North American origin (OR, 1.9; 95%
CI, 1.1–3.4).
Injection drug use is a well-known risk factor for repeat
IE. Repeated bloodstream exposures to particulate matter,
with IDU, can damage heart valves; these valves serve as a
nidus for infection during skin ﬂora-related bacteraemia
episodes [21]. On the other hand, patients with previous IE
have remodelling of the previously infected valve, which can
lead to alteration of blood ﬂow and subsequent formation of
new valve vegetation. Our results validate earlier studies
suggesting IDU and history of previous IE as risk factors for
repeat IE [1,6,8].
Haemodialysis has also been reported as a condition
associated with repeat IE constituting an emerging health-
care-related problem associated with high mortality [2]. A
survey based on the ICE – PCS noted that IE was attributed to
healthcare-related infection in nearly 25% of the patients [12],
conﬁrming ﬁndings from small single-centre studies [22,23].
Fernandez-Hidalgo [24] showed that healthcare-associated IE
represents almost 30% of all episodes of IE and that important
sources of infection were catheter-related bacteraemia and
arteriovenous ﬁstula for haemodialysis. Vigilance for an acute
episode of IE and improved strategies to prevent recurrence
are needed in this group.
Patients from North America were more likely to have
repeat IE than patients from Europe. The reasons for this
ﬁnding are not clear, but are at least partly related to
characteristics of our sample, with the high proportion of
healthcare-associated infections (37.5%) [12,15] that correlate
with geographical distribution. Further studies are needed in
order to clarify this issue.
As seen in previous studies, S. aureus is a leading cause of IE.
Factors such as IDU, increase in implantable devices, and
invasive procedures have contributed to this [12,13,16,25]. In
our study S. aureus was associated with repeat IE on the
bivariable but not on the adjusted analysis. Thus the promi-
nence of S. aureus as a cause of repeat IE may not be due to
intrinsic pathogen-related factors, but rather to its association
with other risks for IE such as IDU and haemodialysis. Our
results emphasize the need to appropriately manage foci (such
as intravascular devices) that can lead to relapse of S. aureus IE
[16,25–27].
Surgical treatment during the initial IE episode was not
associated with repeat IE (p 0.19). This ﬁnding is difﬁcult to
interpret due to the treatment and survivor biases that are
inherent in this observational study.
Finally, some studies identiﬁed prosthetic valve IE as a risk
factor for repeat IE [1,9,10]. Mansur et al. [9] reported that
having prosthetic valve IE in the ﬁrst year after a valve
replacement is a risk factor for having additional episodes.
Similarly, Renzulli et al. [10] showed that prosthetic valve IE
was an independent risk factor for recurrence of IE. We did
not observe a higher risk of repeat IE among patients with
prosthetic valve IE overall (p 0.17); however, additional studies
are needed to address this issue.
Patients with repeat IE had signiﬁcantly higher 1-year
mortality than patients with single-episode IE. Furthermore,
haemodialysis was the single independent predictor of death
among patients with repeat IE. This result emphasizes the
important role of haemodialysis as a predisposing factor in IE,
as suggested by other studies [2,22,23]. Without data about
the cause of death, we are not able to state with certainty the
FIG. 2. Kaplan Meier survival curve for patients with repeat and
single episode IE (no repeat IE).
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reasons for the higher mortality among this cohort of patients.
The higher mortality among patients with repeat IE is not
surprising, and we can speculate that a combination of factors
such as age, co-morbidities and IE-related complications
contribute to the higher mortality.
This study has noteworthy limitations. Although this is the
largest, multinational contemporary analysis of repeat IE, it is
limited by the amount of missing data on follow-up. Details
regarding medical treatment (i.e. antibiotic type and duration)
were not available. Finally, follow-up status beyond 1 year was
not collected in the ICE – PCS.
In conclusion, repeat IE is a clinical problem that results in
high mortality. It is associated with IDU, haemodialysis
dependence and history of previous IE. Clinicians should be
vigilant for repeat IE among susceptible patients and every
effort should be made to eliminate potential foci of infection
among these patients. For high-risk patients such as those on
chronic haemodialysis, strategies to prevent repeat IE are
needed.
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